David Rodman sells multiple Mineralys (NASDAQ: MLYS) share tranches in Q1 2026
Rhea-AI Filing Summary
Mineralys Therapeutics reports multiple sales of Common Stock by David Rodman. The filings list a series of dispositions between
Transactions are characterized as cash or broker‑assisted cashless exercises and list per‑trade share counts and proceeds, indicating routine insider dispositions over the stated period.
Positive
- None.
Negative
- None.
Insights
Series of scheduled insider dispositions by a single reporting person over two months.
The record shows repeated sales by David Rodman from
These appear as routine liquidity events; cashflow recipients are the selling holder(s). Subsequent filings would be required to see aggregated impact on beneficial ownership.
Transactions include both cash and broker‑assisted cashless exercises tied to option exercises.
The excerpt shows exercises dated
Such mixed settlement methods are common for option liquidity; the filing does not state tax treatment or remaining option positions.
FAQ
What insider transactions does MLYS disclose in this Form 144?
Were any option exercises reported in the MLYS excerpt?
How are proceeds shown for the reported transactions in the MLYS filing?
Does the Form 144 excerpt show a change in beneficial ownership for MLYS?